EIKON THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
EIKON THERAPEUTICS, INC. (EIKN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $12.29 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- 2025-06-30: Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month $12.29M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month |
|---|---|
| 2025-06-30 | $12.29M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |